Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aeglea Bio Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AGLE
Nasdaq
8731
https://www.aeglea.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
- Jan 6th, 2023 12:01 pm
Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely
- Jan 2nd, 2023 12:29 pm
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
- Dec 14th, 2022 5:00 pm
Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dec 2nd, 2022 9:05 pm
Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease
- Nov 30th, 2022 3:38 pm
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
- Nov 30th, 2022 12:01 pm
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
- Nov 15th, 2022 9:25 pm
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates
- Nov 3rd, 2022 12:35 pm
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
- Nov 3rd, 2022 11:01 am
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers
- Oct 21st, 2022 4:27 pm
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
- Oct 21st, 2022 4:06 pm
Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment
- Oct 19th, 2022 8:05 pm
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
- Oct 17th, 2022 3:57 pm
FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients
- Oct 4th, 2022 3:05 pm
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program
- Oct 4th, 2022 11:01 am
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
- Aug 29th, 2022 8:05 pm
Trade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of Shares
- Aug 27th, 2022 1:18 pm
Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down
- Aug 25th, 2022 3:52 pm
Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus
- Aug 24th, 2022 4:40 pm
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
- Aug 24th, 2022 12:01 pm
Scroll